Role of the Oral Microbiome in Oral Squamous Cell Carcinoma Progression
口腔微生物组在口腔鳞状细胞癌进展中的作用
基本信息
- 批准号:9975819
- 负责人:
- 金额:$ 16.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-10 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibiotic TherapyAntibodiesBacteriaC57BL/6 MouseCancer cell lineCarcinogensCell ProliferationCellular AssayChronicColonCommunitiesCoupledDataDevelopmentDiseaseEpithelial CellsExhibitsExposure toFusobacterium nucleatumGallbladderGene Expression ProfilingGenesGenetic TranscriptionGnotobioticGoalsGrowthHead and Neck CancerHelicobacter InfectionsHumanHuman MicrobiomeHyperactive behaviorImmuneImmune responseImmunityImmunosuppressionImmunotherapeutic agentInflammationInterventionLeadLeukocytesLinkLower Gastrointestinal TractMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of urinary bladderMediatingMetabolic PathwayModalityMolecularMusMyeloid-derived suppressor cellsNeoplasm MetastasisNeoplastic Cell TransformationOralOral cavityOxidative StressOxidesPasteurella pneumotropicaPathogenicityPathway interactionsPhenotypePlayProductionRecurrenceRegimenRegulatory T-LymphocyteReportingResearchRoleSignal TransductionStomachSurvival RateTestingTongueTransplantationTumor Cell InvasionTumor ImmunityVirulencecancer survivalcarcinogenesiscell growthcell transformationdraining lymph nodedysbiosisgut microbiomehost microbiomein vivoinsightlymph nodesmalignant mouth neoplasmmalignant stomach neoplasmmetatranscriptomicsmicrobiomemouse modelmouth squamous cell carcinomaneoplastic cellnovel strategiesnovel therapeuticsoral microbiomeoutcome forecastoverexpressionpathobiontpathogenpathogenic bacteriapreventresponsetranscriptome sequencingtranscriptomicstumortumor growthtumor initiationtumor microbiometumor progressiontumorigenesistumorigenic
项目摘要
Project Abstract
Head and neck cancer represents the sixth most common malignancy worldwide, and oral squamous cell
carcinomas (OSCC) are the most frequent malignancies in the oral cavity. Despite improvements in prognosis
for many other human cancers, survival rates for OSCC have remained nearly unchanged for decades,
emphasizing the urgent need for new treatment modalities. Mounting evidence indicates that the human
microbiome plays a key role in promoting a variety of cancers, including stomach, colon and gall bladder, via
various mechanisms. In contrast to the lower GI tract, the role of, and mechanisms by which, the oral
microbiome may contribute to OSCC remain obscure. The impetus for this project is that gnotobiotic mouse
models, coupled with functional transcriptomics, offer powerful new approaches to elucidate the mechanisms
that underlie the tumorigenic effects of the oral microbiome in OSCC. In preliminary studies we found that
germfree mice colonized with microbiomes, and challenged with the carcinogen 4-NQO, developed many
more, and larger tumors than mice that remained germfree. Transcriptionally-hyperactive candidate pathogens
were identified, which expressed numerous virulence signatures, paralleling previous findings in human OSCC.
Tumor-infiltrating leukocytes (TIL) appeared to be modulated to an immunosuppressive vs protective
phenotype in microbiome-colonized mice. These findings lead to our central hypothesis, that key pathogenic
species in the oral microbiome promote OSCC progression, at least in part by inducing immunosuppression vs
protective immunity. This will be tested by determining the transcriptionally-hyperactive species that most
strongly promote the growth and metastasis of syngeneic mouse oral cancer (MOC) cell line orthografts in
mouse tongues in vivo. Bacterial metabolic pathways will be characterized by metatranscriptomics, and the
microbiome-modulated immune as well as tumor cell responses by RNASeq. Immune responses induced by
tumorigenic pathogens will be characterized locally and in draining lymph nodes. The function of Treg and
myeloid-derived suppressor cells will be evaluated by abrogation with immunotherapeutic antibodies in vivo.
Direct effects of tumorigenic pathogens on tumor cell growth and invasion will be determined. The goal is to
identify key oral tumorigenic bacteria and their molecular mechanisms that are responsible for promoting
OSCC progression. Successful completion of this project will suggest new microbiome-focused interventions to
reduce OSCC initiation and recurrence, and contribute to the development of next generation therapeutics for
this recalcitrant and devastating disease.
项目摘要
头颈癌是世界上第六大最常见的恶性肿瘤,口腔鳞状细胞癌是世界上第三大最常见的恶性肿瘤。
口腔癌(OSCC)是口腔中最常见的恶性肿瘤。尽管预后有所改善
对于许多其他人类癌症,OSCC的存活率几十年来几乎保持不变,
强调迫切需要新的治疗方式。越来越多的证据表明,人类
微生物组在促进各种癌症,包括胃癌,结肠癌和胆囊癌,
各种机制。与下胃肠道相反,口腔粘膜的作用和机制,
微生物组可能导致OSCC仍然不清楚。这个项目的推动力是,
模型,加上功能转录组学,提供了强大的新方法来阐明机制
这是OSCC中口腔微生物组致瘤作用的基础。在初步研究中,我们发现,
无菌小鼠定植微生物组,并与致癌物4-NQO的挑战,发展了许多
比保持无菌状态的小鼠有更多更大的肿瘤。转录过度活跃的候选病原体
表达了许多毒力特征,与以前在人类OSCC中的发现相似。
肿瘤浸润性白细胞(TIL)似乎被调节为免疫抑制性与保护性
表型在微生物组定殖的小鼠中。这些发现引出了我们的核心假设,即关键致病因素
口腔微生物组中的微生物促进OSCC进展,至少部分是通过诱导免疫抑制,
保护性免疫这将通过确定转录过度活跃的物种来测试,
强烈促进同基因小鼠口腔癌(MOC)细胞系移植物的生长和转移,
小鼠体内舌头。细菌代谢途径将通过元转录组学来表征,
微生物群调节的免疫以及通过RNASeq的肿瘤细胞应答。诱导的免疫应答
致瘤病原体将在局部和引流淋巴结中表征。Treg的功能和
骨髓来源的抑制细胞将通过在体内用免疫抑制抗体消除来评价。
将确定致瘤病原体对肿瘤细胞生长和侵袭的直接影响。目标是
确定关键的口腔致瘤细菌及其分子机制,
OSCC进展。该项目的成功完成将提出新的以微生物组为重点的干预措施,
减少OSCC的发生和复发,并有助于开发下一代治疗方法,
这是一种致命的疾病。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP Stashenko其他文献
PHILIP Stashenko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP Stashenko', 18)}}的其他基金
Forsyth Expansion for the Center for Discovery at the Host-Biofilm Interface
福赛斯宿主生物膜界面发现中心扩建
- 批准号:
7841602 - 财政年份:2010
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
6645428 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
6946804 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
6896024 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
7081394 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
6785422 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
Harvard-SDM/Forsyth Scholar/Faculty Development Program
哈佛-SDM/福赛思学者/教师发展计划
- 批准号:
6459413 - 财政年份:2002
- 资助金额:
$ 16.47万 - 项目类别:
相似海外基金
SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
- 批准号:
2213034 - 财政年份:2023
- 资助金额:
$ 16.47万 - 项目类别:
Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
- 批准号:
10645528 - 财政年份:2023
- 资助金额:
$ 16.47万 - 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
- 批准号:
10736285 - 财政年份:2023
- 资助金额:
$ 16.47万 - 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
- 批准号:
10603486 - 财政年份:2023
- 资助金额:
$ 16.47万 - 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
- 批准号:
449379 - 财政年份:2020
- 资助金额:
$ 16.47万 - 项目类别:
Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
- 批准号:
422034 - 财政年份:2020
- 资助金额:
$ 16.47万 - 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
- 批准号:
nhmrc : 1197866 - 财政年份:2020
- 资助金额:
$ 16.47万 - 项目类别:
Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
- 批准号:
2241853 - 财政年份:2019
- 资助金额:
$ 16.47万 - 项目类别:
Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
- 批准号:
18K07106 - 财政年份:2018
- 资助金额:
$ 16.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
- 批准号:
9788269 - 财政年份:2018
- 资助金额:
$ 16.47万 - 项目类别:














{{item.name}}会员




